Wilson's disease and other neurological copper disorders

The Lancet Neurology

Volumn 14, Issue 1, 2015, Pages 103-113

  Bandmann, Oliver ^a   Weiss, Karl Heinz ^b   Kaler, Stephen G ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER;

GENETICS; HEPATOLENTICULAR DEGENERATION; HUMAN; METABOLISM; NEUROLOGIC DISEASE;

COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 84918590638     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70190-5     Document Type: Review

References (111)

1. Broussolle E, Trocello JM, Woimant F, Lachaux A, Quinn N Samuel Alexander Kinnier Wilson. Wilson's disease, Queen Square and neurology. Rev Neurol (Paris) 2013, 169:927-935.
2. Compston A Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London). Brain. Brain 2009, 132:1997-2001.
3. Cumings JN The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 1948, 71:410-415.
4. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993, 5:327-337.
5. Petrukhin K, Fischer SG, Pirastu M, et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993, 5:338-343.
6. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993, 5:344-350.
7. Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom. Brain 2013, 136:1476-1487.
8. Møller LB, Ott P, Lund C, Horn N Homozygosity for a gross partial gene deletion of the C-terminal end of ATP7B in a Wilson patient with hepatic and no neurological manifestations. Am J Med Genet A 2005, 138:340-343.
9. Ferenci P Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet 2006, 120:151-159.
10. Weiss KH Wilsons Disease. GeneReviews 1993-2014, University of Washington, Seattle. R.A. Pagon, M.P. Adam, H.H. Ardinger (Eds.).
11. Merle U, Weiss KH, Eisenbach C, Tuma S, Ferenci P, Stremmel W Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. BMC Gastroenterol 2010, 10:8.
12. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995, 9:210-217.
13. Shah AB, Chernov I, Zhang HT, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997, 61:317-328.
14. Tarnacka B, Gromadzka G, Rodo M, Mierzejewski P, Czloonkowska A Frequency of His1069Gln and Gly1267Lys mutations in Polish Wilson's disease population. Eur J Neurol 2000, 7:495-498.
15. Bruha R, Marecek Z, Pospisilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011, 31:83-91.
16. Stapelbroek JM, Bollen CW, van Amstel JK, et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 2004, 41:758-763.
17. Gromadzka G, Rudnicka M, Chabik G, Przybyłkowski A, Członkowska A Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilson's disease. J Hepatol 2011, 55:913-919.
18. Schiefermeier M, Kollegger H, Madl C, et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain 2000, 123:585-590.
19. Huster D, Kuhne A, Bhattacharjee A, et al. Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology 2012, 142:947-956.
20. Gu M, Cooper JM, Butler P, et al. Oxidative-phosphorylation defects in liver of patients with Wilson's disease. Lancet 2000, 356:469-474.
21. Zischka H, Lichtmannegger J, Schmitt S, et al. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J Clin Invest 2011, 121:1508-1518.
22. Park RH, McCabe P, Fell GS, Russell RI Wilson's disease in Scotland. Gut 1991, 32:1541-1545.
23. Hahn SH, Lee SY, Jang YJ, et al. Pilot study of mass screening for Wilson's disease in Korea. Mol Genet Metab 2002, 76:133-136.
24. Ohura T, Abukawa D, Shiraishi H, et al. Pilot study of screening for Wilson disease using dried blood spots obtained from children seen at outpatient clinics. J Inherit Metab Dis 1999, 22:74-80.
25. Zappu A, Magli O, Lepori MB, et al. High incidence and allelic homogeneity of Wilson disease in 2 isolated populations: a prerequisite for efficient disease prevention programs. J Pediatr Gastroenterol Nutr 2008, 47:334-338.
26. Walshe JM Cause of death in Wilson disease. Mov Disord 2007, 22:2216-2220.
27. Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilson's disease: Report of 119 cases. Mov Disord 2006, 21:2192-2196.
28. Ferenci P, Członkowska A, Merle U, et al. Late-onset Wilson's disease. Gastroenterology 2007, 132:1294-1298.
29. Ala A, Borjigin J, Rochwarger A, Schilsky M Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology 2005, 41:668-670.
30. Kim JW, Kim JH, Seo JK, et al. Genetically confirmed Wilson disease in a 9-month old boy with elevations of aminotransferases. World J Hepatol 2013, 5:156-159.
31. Rosen JM, Kuntz N, Melin-Aldana H, Bass LM Spasmodic muscle cramps and weakness as presenting symptoms in Wilson disease. Pediatrics 2013, 132:e1039-e1042.
32. Svetel M, Kozić D, Stefanova E, Semnic R, Dragasevic N, Kostic VS Dystonia in Wilson's disease. Mov Disord 2001, 16:719-723.
33. Risvoll H, Kerty E To test or not? The value of diagnostic tests in cervical dystonia. Mov Disord 2001, 16:286-289.
34. Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007, 86:112-121.
35. Dening TR, Berrios GE, Walshe JM Wilson's disease and epilepsy. Brain 1988, 111:1139-1155.
36. Verma R, Patil TB, Lalla RS Acute extrapyramidal syndrome and seizures as heralding manifestation of Wilson disease. Neurol India 2012, 60:363-364.
37. Ingster-Moati I, Bui Quoc E, Pless M, et al. Ocular motility and Wilson's disease: a study on 34 patients. J Neurol Neurosurg Psychiatry 2007, 78:1199-1201.
38. Svetel M, Potrebić A, Pekmezović T, et al. Neuropsychiatric aspects of treated Wilson's disease. Parkinsonism Relat Disord 2009, 15:772-775.
39. Zimbrean PC, Schilsky ML Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry 2014, 36:53-62.
40. Srinivas K, Sinha S, Taly AB, et al. Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge!. J Neurol Sci 2008, 266:104-108.
41. Wenisch E, De Tassigny A, Trocello JM, Beretti J, Girardot-Tinant N, Woimant F Cognitive profile in Wilson's disease: a case series of 31 patients. Rev Neurol (Paris) 2013, 169:944-949.
42. Iwański S, Seniów J, Leśniak M, Litwin T, Członkowska A Diverse attention deficits in patients with neurologically symptomatic and asymptomatic Wilson's disease. Neuropsychology 2014, published online June 2. http://dx.doi.org/10.1037/neu0000103.
43. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012, 56:671-685. European Association for Study of Liver.
44. Ala A, Walker AP, Keyoumars A, Dooley JS, Schilsky ML Wilson's disease. Lancet 2007, 369:397-408.
45. Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011, 140:1189-1198.
46. Nicastro E, Ranucci G, Vajro P, Vegnente A, Iorio R Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology 2010, 52:1948-1956.
47. Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 1992, 15:609-615.
48. Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepatol 2005, 3:811-818.
49. Prashanth LK, Sinha S, Taly AB, Vasudev MK Do MRI features distinguish Wilson's disease from other early onset extrapyramidal disorders? An analysis of 100 cases. Mov Disord 2010, 25:672-678.
50. Trocello JM, Woimant F, El Balkhi S, et al. Extensive striatal, cortical, and white matter brain MRI abnormalities in Wilson disease. Neurology 2013, 81:1557.
51. Fritzsch D, Reiss-Zimmermann M, Trampel R, Turner R, Hoffmann KT, Schäfer A Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol 2014, 49:299-306.
52. Oertel WH, Tatsch K, Schwarz J, et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol 1992, 32:743-748.
53. Page RA, Davie CA, MacManus D, et al. Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease. Neurology 2004, 63:638-643.
54. Skowrońska M, Litwin T, Dziezyc K, Wierzchowska A, Członkowska A Does brain degeneration in Wilson disease involve not only copper but also iron accumulation?. Neurol Neurochir Pol 2013, 47:542-546.
55. Litwin T, Dziezyc K, Poniatowska R, Członkowska A Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurol Neurochir Pol 2013, 47:393-397.
56. Curtis D, Durkie M, Balac P, et al. A study of Wilson disease mutations in Britain. Hum Mutat 1999, 14:304-311.
57. Dufernez F, Lachaux A, Chappuis P, et al. Wilson disease in offspring of affected patients: report of four French families. Clin Res Hepatol Gastroenterol 2013, 37:240-245.
58. Weiss KH, Stremmel W Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. Curr Gastroenterol Rep 2012, 14:1-7.
59. Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 2013, 11:1028-1035.
60. Brewer GJ, Askari F, Dick RB, et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 2009, 154:70-77.
61. Chen DB, Feng L, Lin XP, et al. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS One 2012, 7:e37709.
62. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998, 132:264-278.
63. Linn FHH, Houwen RHJ, van Hattum J, van der Kleij S, van Erpecum KJ Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 2009, 50:1442-1452.
64. Dziezyc K, Karliński M, Litwin T, Członkowska A Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients. Eur J Neurol 2014, 21:332-337.
65. Walshe JM, Dixon AK Dangers of non-compliance in Wilson's disease. Lancet 1986, 1:845-847.
66. Medici V, Mirante VG, Fassati LR, et al. Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl 2005, 11:1056-1063. the Monotematica AISF 2000 OLT Study Group.
67. Schilsky ML Transplantation for inherited metabolic disorders of the liver. Transplant Proc 2013, 45:455-462.
68. Weiss KH, Schäfer M, Gotthardt DN, et al. Outcome and development of symptoms after orthotopic liver transplantation for Wilson disease. Clin Transplant 2013, 27:914-922.
69. Hölscher S, Leinweber B, Hefter H, et al. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol 2010, 64:83-87.
70. Pal PK, Sinha S, Pillai S, Taly AB, Abraham RG Successful treatment of tremor in Wilson's disease by thalamotomy: a case report. Mov Disord 2007, 22:2287-2290.
71. Kaler SG ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol 2011, 7:15-29.
72. Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med 2008, 358:605-614.
73. Donsante A, Yi L, Zerfas PM, et al. ATP7A gene addition to the choroid plexus results in long-term rescue of the lethal copper transport defect in a Menkes disease mouse model. Mol Ther 2011, 19:2114-2123.
74. Kennerson ML, Nicholson GA, Kaler SG, et al. Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am J Hum Genet 2010, 86:343-352.
75. Kaler SG Inborn errors of copper metabolism. Handb Clin Neurol 2013, 113:1745-1754.
76. Yi L, Donsante A, Kennerson ML, Mercer JF, Garbern JY, Kaler SG Altered intracellular localization and valosin-containing protein (p97 VCP) interaction underlie ATP7A-related distal motor neuropathy. Hum Mol Genet 2012, 21:1794-1807.
77. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68:857-864. the ITALSGEN Consortium.
78. Montpetit A, CÔté S, Brustein E, et al. Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. PLoS Genet 2008, 4:e1000296.
79. Martinelli D, Travaglini L, Drouin CA, et al. MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. Brain 2013, 136:872-881.
80. Huppke P, Brendel C, Kalscheuer V, et al. Mutations in SLC33A1 cause a lethal autosomal-recessive disorder with congenital cataracts, hearing loss, and low serum copper and ceruloplasmin. Am J Hum Genet 2012, 90:61-68.
81. Stamelou M, Tuschl K, Chong WK, et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Mov Disord 2012, 27:1317-1322.
82. Quadri M, Federico A, Zhao T, et al. Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet 2012, 90:467-477.
83. Tuschl K, Clayton PT, Gospe SM, et al. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet 2012, 90:457-466.
84. Di Toro Mammarella L, Mignarri A, Battisti C, et al. Two-year follow-up after chelating therapy in a patient with adult-onset parkinsonism and hypermanganesaemia due to SLC30A10 mutations. J Neurol 2014, 261:227-228.
85. Kerkhof M, Honkoop P Never forget aceruloplasminemia in case of highly suggestive Wilson's disease score. Hepatology 2014, 59:1645-1647.
86. Pfeiffenberger J, Gotthardt DN, Herrmann T, et al. Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int 2012, 32:165-170.
87. Kono S Aceruloplasminemia: an update. Int Rev Neurobiol 2013, 110:125-151.
88. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008, 60:200-205.
89. Ogimoto M, Anzai K, Takenoshita H, et al. Criteria for early identification of aceruloplasminemia. Intern Med 2011, 50:1415-1418.
90. Jellinger KA The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. Int Rev Neurobiol 2013, 110:1-47.
91. Noda Y, Asada M, Kubota M, et al. Copper enhances APP dimerization and promotes Aβ production. Neurosci Lett 2013, 547:10-15.
92. Squitti R, Simonelli I, Ventriglia M, et al. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. J Alzheimers Dis 2014, 38:809-822.
93. Ventriglia M, Bucossi S, Panetta V, Squitti R Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2012, 30:981-984.
94. Squitti R, Bressi F, Pasqualetti P, et al. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 2009, 72:50-55.
95. Singh I, Sagare AP, Coma M, et al. Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance. Proc Natl Acad Sci USA 2013, 110:14771-14776.
96. Squitti R, Polimanti R, Bucossi S, et al. Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease. Rejuvenation Res 2013, 16:3-10.
97. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013, 45:1452-1458. the European Alzheimer's Disease Initiative (EADI), the Genetic and Environmental Risk in Alzheimer's Diseasethe Genetic and Environmental Risk in Alzheimer's Disease, the Alzheimer's Disease Genetic Consortiumthe Alzheimer's Disease Genetic Consortium, the Cohorts for Heart and Aging Research in Genomic Epidemiologythe Cohorts for Heart and Aging Research in Genomic Epidemiology.
98. Davies P, Wang X, Sarell CJ, et al. The synucleins are a family of redox-active copper binding proteins. Biochemistry 2011, 50:37-47.
99. Binolfi A, Rodriguez EE, Valensin D, et al. Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein. Inorg Chem 2010, 49:10668-10679.
100. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
101. Zhao HW, Lin J, Wang XB, et al. Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson's disease. PLoS One 2013, 8:e83060.
102. Jin L, Wang J, Zhao L, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011, 134:50-58.
103. Bharucha KJ, Friedman JK, Vincent AS, Ross ED Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 2008, 255:1957-1962.
104. Ayton S, Lei P, Duce JA, et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 2013, 73:554-559.
105. Olivieri S, Conti A, Iannaccone S, et al. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 2011, 31:18568-18577.
106. Lutsenko S Atp7b-/- mice as a model for studies of Wilson's disease. Biochem Soc Trans 2008, 36:1233-1238.
107. Lang PA, Schenck M, Nicolay JP, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007, 13:164-170.
108. Leinweber B, Möller JC, Scherag A, et al. Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease. Mov Disord 2008, 23:54-62.
109. Zhang S, Chen S, Li W, et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum Mol Genet 2011, 20:3176-3187.
110. Roybal JL, Endo M, Radu A, et al. Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease. Gene Ther 2012, 19:1085-1094.
111. Bruha R, Vitek L, Marecek Z, et al. Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. J Inherit Metab Dis 2012, 35:541-548.